Medicine and Dentistry
Systemic Scleroderma
100%
Interstitial Lung Disease
100%
Diseases
55%
Drug Therapy
44%
Mycophenolic Acid
44%
Scleroderma
44%
Dyspnea
22%
Disease Burden
22%
Clinical Trial
22%
Quality of Life
11%
Side Effect
11%
Blood Proteins
11%
Blood Cell
11%
Lung Injury
11%
Infection
11%
Nintedanib
11%
Activities of Daily Living
11%
Alternative Medication
11%
Tocilizumab
11%
Biological Marker
11%
Translational Research
11%
RNA Sequence
11%
Antifibrotic Agent
11%
Air Sac
11%
Exercise
11%
Silo-Filler's Disease
11%
Pulmonary Fibrosis
11%
Immune Response
11%
Interleukin-6
11%
Observational Study
11%
Lung Volume
11%
Immunosuppressive Drug
11%
Autoimmune Disease
11%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Sclerosis
100%
Interstitial Lung Disease
100%
Disease
77%
Mycophenolic Acid
44%
Scleroderma
44%
Clinical Trial
22%
Dyspnea
22%
RNA-Sequencing
11%
Infection
11%
Plasma Protein
11%
Biological Marker
11%
Antifibrotic Agent
11%
Side Effect
11%
Observational Study
11%
Nintedanib
11%
Tocilizumab
11%
Lung Disease
11%
Lung Injury
11%
Autoimmune Disease
11%
Immunosuppressive Agent
11%
Lung Fibrosis
11%